Category: Bio & Healthcare

Brokerage : Hana Securities Analyst : Seona Kim (RA: Changkeun Yoo) Investment Rating : BUY (Maintained) Target Price : KRW 580,000 (Maintained) Core Momentum : Execution of a USD 579 Million exclusive licensing agreement with Biogen brings Q1 cumulative upfront payments to ~KRW 59.5 Billion (combining GSK and Biogen), supported by sequential catalysts including April…

Read More “[Research] Alteogen (196170) – Hana Securities | Exclusive Biogen Licensing Deal · ~USD 40M Q1 Cumulative Upfronts · Rich Q2 Catalysts Ahead / 2026-03-26” »

Brokerage : Mirae Asset Securities Analyst : Seungmin Kim Investment Rating : Not Rated Target Price : – Core Momentum : Re-rating of the IGF1R-targeting Grabody-B platform following Denali’s initial BBB shuttle FDA approval, alongside upcoming ABL001 Phase 2/3 trial data readout in April 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities…

Read More “[Research] ABL Bio (298380) – Mirae Asset Securities | BBB Shuttle Re-rating · IGF1R Competitiveness · ABL001 Data Readout / 2026-03-26” »

Brokerage : Shinhan Securities Analyst : Hocheol Lee, Minyong Eom Investment Rating : Not Rated Target Price : – Core Momentum : Acceleration into a large-scale licensing phase supported by upcoming 1H clinical readouts for LCB71 and LCB84 alongside clinical track records with global big pharma 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Read More “[Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24” »

Brokerage : Shinhan Securities Analyst : Minyong Eom, Seokhyeon Yoon Investment Rating : BUY (Maintained) Target Price : KRW 570,000 (Maintained) Core Momentum : The UK High Court’s favorable initial ruling against Halozyme’s infringement counterclaims sets a positive precedent for European and US patent proceedings, while multiple upcoming out-licensing deals are expected to outweigh Keytruda…

Read More “[Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23” »

Brokerage : Hana Securities Analyst : Seona Kim (RA: Changkeun Yoo) Investment Rating : BUY (Maintained) Target Price : KRW 580,000 (Maintained) Core Momentum : Robust pipeline execution led by AZ rilvegostomig Phase 1 entry and Enhertu progress, with Keytruda royalty adjustments sufficiently reflected in the valuation and expectations for new large-scale out-licensing deals maintaining…

Read More “[Research] Alteogen (196170) – Hana Securities | Core Business on Track · Favorable Deal Outlook · Keytruda Royalty Impact Reflected / 2026-02-19” »

Brokerage : Kiwoom Securities Analyst : Heemin Heo Investment Rating : BUY (Maintain) Target Price : KRW 240,000 (Maintain) Core Momentum : Downward valuation of ABL301 due to Sanofi’s clinical timeline adjustment offset by upgraded ABL001 pricing potential, Q1 Phase 3 readouts, and intact Grabody B platform validity 📊 1. [Valuation & Key Financial Metrics]…

Read More “[Research] ABL Bio (298380) – Kiwoom Securities | ABL301 Deprioritization · ABL001 Valuation · Grabody B Validity / 2026-02-02” »

Brokerage : Shinhan Securities Analyst : Minyong Eom, Hocheol Lee Investment Rating : Not Rated Target Price : – Core Momentum : Enhanced clinical differentiation for ABL301 under Sanofi’s strategic trial refinement alongside pipeline scalability into genetic medicines and muscle shuttles for Grabody-B 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…

Read More “[Research] ABL Bio (298380) – Shinhan Securities | Sanofi Strategy · Clinical Differentiation · Platform Expansion / 2026-02-02” »

Brokerage : DS Investment & Securities Analyst : Min-jeong Kim Investment Rating : N/R Target Price : N/R Core Momentum : Intrinsic Grabody B platform validity reinforced despite Sanofi’s ABL301 clinical realignment, with added upside from Ionis-partnered muscle shuttle expansion in 1H26 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities & Business…

Read More “[Research] ABL Bio (298380) – DS Investment & Securities | Sanofi Strategy · Grabody B Validity · Muscle Shuttle Expansion / 2026-02-02” »

Brokerage : Yuanta Securities Analyst : Hyunsoo Ha Investment Rating : BUY (Maintain) Target Price : KRW 280,000 (Upward) Core Momentum : Target price upgraded on Givastomig’s added valuation in CLDN18.2 low-expression patients and rising BBB platform demand, alongside two bispecific ADCs entering the clinic within the year 📊 1. [Valuation & Key Financial Metrics]…

Read More “[Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29” »

Brokerage : Mirae Asset Securities Analyst : Mihwa Seo Investment Rating : Buy (Maintain) Target Price : KRW 230,000 (Upward) Core Momentum : Value realization across key ADC assets through multiple 2026 clinical readouts, paving the way for organic technology transfers 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities & Business Outlook]…

Read More “[Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26” »